HC Wainwright Issues Optimistic Outlook for SAGE Earnings

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Equities researchers at HC Wainwright boosted their Q1 2025 earnings per share estimates for shares of Sage Therapeutics in a research note issued to investors on Wednesday, February 12th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will post earnings of ($1.11) per share for the quarter, up from their previous estimate of ($1.54). HC Wainwright has a “Neutral” rating and a $12.00 price objective on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.46) per share. HC Wainwright also issued estimates for Sage Therapeutics’ Q2 2025 earnings at ($1.05) EPS, Q3 2025 earnings at ($1.00) EPS, Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($4.14) EPS, FY2026 earnings at ($3.56) EPS, FY2027 earnings at ($2.86) EPS, FY2028 earnings at ($2.63) EPS and FY2029 earnings at ($1.84) EPS.

A number of other brokerages have also recently issued reports on SAGE. Needham & Company LLC reiterated a “hold” rating on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Scotiabank lowered their price target on Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating for the company in a research report on Wednesday, February 12th. Royal Bank of Canada upgraded shares of Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price target on the stock in a research note on Thursday, November 21st. Stifel Nicolaus reduced their price objective on shares of Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating for the company in a research note on Monday, December 16th. Finally, Oppenheimer dropped their target price on shares of Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Wednesday, October 30th. Three analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $9.65.

Sage Therapeutics Stock Down 0.6 %

Shares of SAGE opened at $7.14 on Monday. The stock has a market cap of $436.75 million, a P/E ratio of -1.28 and a beta of 0.94. The business’s 50 day moving average price is $6.40 and its 200-day moving average price is $6.85. Sage Therapeutics has a 52 week low of $4.62 and a 52 week high of $26.25.

Sage Therapeutics (NASDAQ:SAGE) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%.

Hedge Funds Weigh In On Sage Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Picton Mahoney Asset Management lifted its position in Sage Therapeutics by 126.0% in the fourth quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 3,581 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Sage Therapeutics in the fourth quarter valued at $49,000. Ieq Capital LLC bought a new stake in shares of Sage Therapeutics in the 4th quarter worth about $57,000. US Bancorp DE lifted its holdings in shares of Sage Therapeutics by 22.3% in the 4th quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 2,268 shares during the last quarter. Finally, Teacher Retirement System of Texas boosted its stake in shares of Sage Therapeutics by 21.6% during the 4th quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company’s stock worth $75,000 after purchasing an additional 2,446 shares during the period. Hedge funds and other institutional investors own 99.22% of the company’s stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.